Anti-Aging
Ipamorelin
Ipamorelin safety evidence is limited and route-specific. FDA identifies potential immunogenicity and insufficient information for some injection routes.
At a glance
Ipamorelin safety evidence is limited and route-specific. FDA identifies potential immunogenicity and insufficient information for some injection routes.
What is ipamorelin?
Ipamorelin is an experimental ghrelin-receptor agonist, often described as a growth-hormone secretagogue. Ghrelin-receptor signaling also has effects on gastrointestinal motility, which explains why human research has examined recovery of bowel function after surgery.
A plausible mechanism does not establish that a medicine improves muscle growth, sleep, body composition or healthy aging. Claims that a peptide is selective or “natural” are not substitutes for clinical safety evidence.
Sources: [ipamorelin-trial] [fda-safety]
The postoperative-ileus trial
A 2014 phase 2 randomized, double-blind, placebo-controlled study evaluated intravenous ipamorelin after small- or large-bowel resection. It enrolled 117 patients; 114 were included in the safety and modified intention-to-treat populations. The main efficacy question was how quickly patients could tolerate a standardized solid meal.
Median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, but the difference was not statistically significant (p = 0.15). The authors reported no significant differences in the key or secondary efficacy analyses.
The authors described treatment as well tolerated in this short proof-of-concept study. That conclusion does not establish safety for prolonged use, other injection routes, different formulations or wellness uses in people who have not had surgery.
Sources: [ipamorelin-trial]
What FDA's safety assessment adds
FDA identifies potential immunogenicity, aggregation and peptide-related impurities for compounded ipamorelin acetate. Its assessment notes serious adverse events, including death, in the intravenous gastric-motility study. Reporting an event does not by itself prove that the drug caused it.
FDA also says it has not identified adequate safety information for certain other injectable routes. Findings from intravenous administration cannot simply be transferred to a different route. Neither a short tolerability report nor a supplier's purity statement establishes long-term clinical safety.
Sources: [fda-safety]
Approval and product-quality questions
The cited research and FDA compounding assessment are not an approved prescribing label for anti-aging or body-composition treatment. A clinic offering a product does not establish approval or a favorable benefit-risk balance for the proposed use.
Ask exactly which substance and formulation are being offered, what human evidence supports the intended goal, and whether the route matches the research. The uncertainty includes both the biological effects of the peptide and the quality of the particular preparation.
Sources: [fda-safety]
Combining ipamorelin with other peptides
The postoperative study was not a test of a CJC-1295/ipamorelin wellness combination. Its results cannot establish the safety of that regimen. FDA separately identifies safety concerns for both substances.
Discuss all medicines and supplements with a clinician. Unknown interactions should remain labeled unknown, not described as absent. This guide does not supply a dose, injection preparation method or cycle schedule because the cited evidence does not validate such a protocol for wellness use.
Sources: [fda-safety] [ipamorelin-trial]
Frequently asked questions
These FAQs use the sources listed below. They are not independently clinically reviewed.
How does ipamorelin work?
Ipamorelin is discussed as a growth-hormone-releasing peptide, but claims of selective action are not proof of safety. FDA identifies limited safety information for some routes and reports serious adverse events in an intravenous gastric-motility study. A study using one route does not establish safety by another.
Sources: [fda-safety]
Can ipamorelin be combined with other peptides?
Do not assume that combining ipamorelin with CJC-1295 is safe or more effective. The cited FDA source flags safety concerns for both substances and does not establish a validated combination regimen. Discuss the specific proposal and uncertainties with a qualified clinician.
Sources: [fda-safety]
Sources and reading notes
Sources support the cited sections or FAQs, not every statement in a legacy overview. A source link is not an endorsement of a product or treatment.
[fda-safety] U.S. Food and Drug Administration — Compounding substances that may present significant safety risks
Substance-specific safety concerns; inclusion or removal from a compounding list is not marketing approval.
[ipamorelin-trial] Peer-reviewed journal / PubMed — Beck et al. (2014): Ipamorelin for postoperative ileus
About this entry
Article updated: .
AI-assisted source synthesis prepared for Peptide Directory. No independent clinical review has been performed.